- Home
- RDVT vs ANAB Comparison
RDVT vs ANAB Comparison
Compare RDVT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- ANAB
- Stock Information
- Founded
- RDVT 2017
- ANAB 2005
- Country
- RDVT United States
- ANAB United States
- Employees
- RDVT N/A
- ANAB N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- RDVT Technology
- ANAB Health Care
- Exchange
- RDVT Nasdaq
- ANAB Nasdaq
- Market Cap
- RDVT 646.6M
- ANAB 621.1M
- IPO Year
- RDVT N/A
- ANAB 2017
- Fundamental
- Price
- RDVT $47.45
- ANAB $23.17
- Analyst Decision
- RDVT
- ANAB Buy
- Analyst Count
- RDVT 0
- ANAB 10
- Target Price
- RDVT N/A
- ANAB $44.25
- AVG Volume (30 Days)
- RDVT 140.2K
- ANAB 775.6K
- Earning Date
- RDVT 08-06-2025
- ANAB 08-04-2025
- Dividend Yield
- RDVT 0.63%
- ANAB N/A
- EPS Growth
- RDVT N/A
- ANAB N/A
- EPS
- RDVT 0.61
- ANAB N/A
- Revenue
- RDVT $79,681,000.00
- ANAB $111,872,000.00
- Revenue This Year
- RDVT $15.93
- ANAB N/A
- Revenue Next Year
- RDVT $16.87
- ANAB $24.39
- P/E Ratio
- RDVT $77.49
- ANAB N/A
- Revenue Growth
- RDVT 26.30
- ANAB 387.20
- 52 Week Low
- RDVT $20.89
- ANAB $12.21
- 52 Week High
- RDVT $51.10
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- RDVT 54.43
- ANAB 56.01
- Support Level
- RDVT $47.11
- ANAB $22.46
- Resistance Level
- RDVT $48.68
- ANAB $24.17
- Average True Range (ATR)
- RDVT 1.82
- ANAB 1.72
- MACD
- RDVT -0.19
- ANAB -0.01
- Stochastic Oscillator
- RDVT 77.34
- ANAB 73.23
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).